Tassorelli, Cristina http://orcid.org/0000-0003-1513-2113
Barbanti, Piero
Finocchi, Cinzia
Geppetti, Pierangelo
Kokturk, Pinar
Russo, Antonio
Sacco, Simona
Cepparulo, Mario
Ambrosini, Anna
Bandettini, Monica
Bartolini, Marco
Benedetto, Chiara
Brighina, Filippo
Cevoli, Sabina
Coppola, Gianluca
De Simone, Roberto
Di Fiore, Paola
D’Onofrio, Florindo
Gori, Sara
Granato, Antonio
Guerzoni, Simona
Iannacchero, Rosario
Messina, Stefano
Perini, Francesco
Prudenzano, Maria Pia
Rainero, Innocenzo
Rao, Renata
Reggio, Ester
Sarchielli, Paola
Sette, Giuliano
Usai, Susanna
Valente, Mariarosaria
Vernieri, Fabrizio
,
Funding for this research was provided by:
Teva Pharmaceutical Industries
Article History
Received: 26 October 2023
Accepted: 23 January 2024
First Online: 1 March 2024
Declarations
:
: The protocol has been approved by the Independent Ethics Committee/Institutional Review Board in all 11 participating European countries (Czech Republic, Denmark, Finland, Greece, Italy, Norway, Portugal, Spain, Sweden, Switzerland, and the UK), as required by local regulations, and all relevant local data protection laws are followed. Informed consent was obtained from all patients before inclusion in the study; patients agreed for their clinical data to be recorded anonymously, retaining the right to withdraw their consent at any time during the study.
: CT has received consulting fees or speaking honoraria from AbbVie, Dompé, Lilly, Lundbeck, Novartis, and Pfizer; has received financial support for attending meetings from Lundbeck and Ipsen; is the past-President of the International Headache Society.PB has received consulting fees from AbbVie, Allergan, Angelini, Assosalute, Bayer, Eli-Lilly, Fondazione Ricerca e Salute, Lundbeck, MSD, Novartis, Teva, Visufarma, and Zambon; has received payment or honoraria from AbbVie, Allergan, Angelini, Bayer, Eli-Lilly, Lundbeck, MED, MSD, New Penta, Novartis, Stx-Med, Teva, Visufarma, and Zambon; has received support for attending meetings and/or travel from Lundbeck, Novartis, Teva, and Visufarma; has participated on a data safety monitoring board or advisory board for AbbVie, Allergan, Angelini, Bayer, Eli-Lilly, Lundbeck, New Penta, Novartis, Stx-Med, Teva, Visufarma, and Zambon; and has received other financial or non-financial interests from AbbVie, Amgen, Alder, Allergan, Biohaven, ElectroCore, Eli-Lilly, GSK, Lundbeck, New Penta, Noema Pharma, Novartis, and Teva.MC is an employee of Teva Pharmaceuticals and has received stock or stock options from Teva.SS has received grants or contracts from Novartis, and Uriach; has received consulting fees from AbbVie, Abbott, Allergan, AstraZeneca, Lilly, Lundbeck, NovoNordisk, and Pfizer; has received support for attending meetings and/or travel from Lilly, Lundbeck, Novartis, and Teva; is the President Elect for the European Stroke Organisation and second Vice-President for the European Headache Federation; and has received receipt of equipment, materials, drugs, medical writing gifts or other services from AbbVie, Allergan, and NovoNordisk.AR has received speaker honoraria from Allergan, Lilly, Novartis, Teva, and Pfizer, and serves as an Associate Editor of Frontiers in Neurology (Headache Medicine and Facial Pain session).CF has received payments or honoraria from AbbVie, Lilly, Lundbeck, Novartis, and Teva, and is the President of Anircef.PK is an employee of Teva Pharmaceuticals.